



## **FOR IMMEDIATE RELEASE**

### **Global Media Contacts:**

David Schull or Ian Stone  
Russo Partners  
+1 212-845-4271  
+1 619-528-2220  
david.schull@russopartnersllc.com  
ian.stone@russopartnersllc.com

David Kujawa  
OrbusNeich  
+1 954-730-0711 (office)  
+1 305-733-7216 (mobile)  
dkujawa@orbusneich.com

### **OrbusNeich's Combo™ Bio-engineered Sirolimus-Eluting Stent Featured in Live Case Demonstration at AICT**

SINGAPORE, July 2, 2010 – OrbusNeich announced that their next generation Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) was featured today in a live case demonstration at the 6th Asian Interventional Cardiovascular Therapeutics 2010 (AICT) in Singapore.

Huay Cheem Tan, M.B.B.S., of the National University Hospital in Singapore, performed the live case at the National University Heart Centre, National University Hospital, Singapore. The patient, a 56 year old male, had a single lesion in the left circumflex artery. The Combo Stent placed was 3.0 mm in diameter by 18 mm in length.

OrbusNeich's latest development, the Combo Stent, combines the pro-healing technology used in the company's Genous™ Bio-engineered R stent™ for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation.

"We have had a very positive experience with the Genous stent in patients with ST-elevation myocardial infarction, or STEMI, where the prohealing approach of Genous technology has safely addressed concerns that the use of drug-eluting stents in this subgroup may delay stent endothelialization and increase the likelihood of stent thrombosis," said Dr. Tan. "Now the Combo Stent, by combining the Genous technology with a low dose drug elution, can potentially make drug-eluting stents safer. The live case was a great opportunity to demonstrate the Combo Stent's value to the interventional cardiology community at AICT."

The Combo Stent is currently under investigation in a prospective, randomized, multicenter study called REMEDEE (**R**andomized **E**valuation of an ablu**M**inal sirolimus coat**ED** bio-**E**ngineered st**Ent**) to demonstrate its safety and effectiveness compared to the TAXUS® Liberté® paclitaxel-eluting stent, a drug-eluting stent (DES), in the treatment of single *de novo* native coronary lesions ranging in diameter from  $\geq 2.5$  mm to  $\leq 3.5$  mm and  $\leq 20$  mm in length. The primary endpoint of the study is in-stent late lumen loss of the Combo Stent compared to DES at nine months post-procedure. The study has currently enrolled more than half of the planned 180 patients at 20 sites in Asia, Australia, Europe and South America.

### **About Genous**

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

### **About OrbusNeich**

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit [www.OrbusNeich.com](http://www.OrbusNeich.com).

###